Mary Jane Geiger - Concepedia

Author

Mary Jane Geiger

Eli Lilly (United States)

Also Known As

MARY J. GEIGER, MARY JANE GEIGER, Mary J. Geiger, Mary Jane Geiger

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)University of California, San Francisco Columbia University University of California San Diego Duke Medical Center

About

Mary Jane Geiger is an author at Eli Lilly (United States) specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	277
2	Engineering	1	1	14
3	Health Sciences	1	1	31
4	Public Health	1	1	23
5	Biochemistry	1	1	29

Mary Jane Geiger

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women Elizabeth Barrett‐Connor, Lori Mosca, Peter Collins, New England Journal of Medicine	2006	1K
Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women László B. Tankó, Claus Christiansen, David A. Cox, Journal of Bone and Mineral Research	2005	533
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet, European Heart Journal	2015	530
Implantable Cardioverter-Defibrillators and Pregnancy Andrea Natale, Theresa Davidson, Mary Jane Geiger, Circulation	1997	206
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus Keith C. Ferdinand, William B. White, David A. Calhoun, Hypertension	2014	140
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease Lori Mosca, Deborah Grady, Elizabeth Barrett‐Connor, Stroke	2008	108
Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial Peter Collins, Lori Mosca, Mary Jane Geiger, Circulation	2009	106
Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial Elizabeth Barrett‐Connor, Jane A. Cauley, Pandurang M. Kulkarni, Journal of Bone and Mineral Research	2004	73
Recurrence of neurocardiogenic syncope without pharmacologic interventions Andrea Natale, Mary Jane Geiger, Cheryl Maglio, The American Journal of Cardiology Electrophysiological EvaluationCardiovascular DiseaseNeurocardiogenic SyncopeNeurologyMedicine	1996	53
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women Elizabeth Barrett‐Connor, Lori Mosca, Peter Collins, Obstetrical & Gynecological Survey	2006	52

Page 1